封面
市场调查报告书
商品编码
1883966

Frost Radar:实验室自动化系统,2025

Frost Radar: Laboratory Automation Systems, 2025

出版日期: | 出版商: Frost & Sullivan | 英文 20 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

基准化分析体系旨在鼓励企业行为:透过创新推动新业务的创建和成长。

病理检测人才短缺、准确性问题以及价格和资源分配不均等问题,仍是诊断产业面临的持续挑战。自动化是一个涵盖流程和方法的广泛概念,旨在简化工作流程、缩短时间并应对日益增长的工作量,已成为应对这些挑战的关键解决方案。实验室自动化整合了硬体和软体系统,可提供多种解决方案,包括降低成本、最大限度地减少人为错误、提高临床工作流程的可靠性、简化药物和疫苗研发以及简化研究方法。

自动化系统的日益普及、对专业检测需求的成长以及CRISPR、聚合物开发和CAR-T疗法等新兴科学的影响正在重塑市场模式。自动化液体处理和检体管理系统市场已趋于成熟且竞争激烈,而工作流程自动化系统市场则展现出强劲的成长潜力,这主要得益于一些小型供应商的涌现,他们提供云端基础的工作流程管理、模拟和执行编配。 Frost Radar™对提供自动化液体处理、样品管理和工作流程自动化解决方案的公司进行了基准测试。筛选标准包括在至少两个细分市场中的收入份额和产品系列实力。收入份额分为「高」(超过10%)、「中」(2-9%)和「低」(低于2%或缺乏强大的产品系列)三个等级。本分析重点在于2021年至2024年间透过这些解决方案获得收入的13家公司。

弗若斯特沙利文公司对产业内的众多公司进行分析。根据领导力及其他特征筛选出的公司将接受进一步分析,并根据10项成长和创新标准进行基准测试,从而揭示其在弗若斯特雷达™中的位置。本出版品将分析每家公司的优势以及与这些优势最契合的机会,从而呈现弗若斯特雷达™竞争概况。

目录

策略问题与成长环境

Frost Radar™:实验室自动化系统

Frost Radar™:采取行动的公司

  • Abbott
  • Agilent Technologies
  • Azenta Life Sciences
  • BD
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Eppendorf
  • Hamilton Company
  • Revvity
  • Roche Diagnostics
  • Siemens Healthineers
  • Tecan
  • Thermo Fisher Scientific

最佳实践和成长机会

霜冻雷达分析

后续步骤:利用 Frost Radar 赋能关键相关人员

  • 登上 Frost Radar 的意义
  • CEO成长团队
  • 投资者
  • 顾客
  • 董事会

下一步

免责声明

简介目录
Product Code: PG2P-55

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources remain persistent challenges for the diagnostics sector. Automation, a broad concept encompassing processes and practices that streamline workflows, save time, and manage increasing workloads, has become a key response to these issues. By combining hardware and software systems, laboratory automation delivers multiple solutions that reduce costs, minimize human error, and enhance the reliability of clinical workflows, the development of medicines and vaccines, and the efficiency of research processes.

The market is being shaped by the growing adoption of automation systems, alongside increased demand for specialized testing and the influence of new sciences, such as CRISPR, large molecule development, and CAR-T therapy. While the automated liquid handling and sample management system markets are well-established and competitive, the workflow automation system market shows strong growth potential, driven in part by small and midsized vendors offering cloud-based orchestration for workflow management, simulation, and execution. This Frost Radar™ benchmarked companies and their automated liquid handling, sample management, and workflow automation solutions. Companies were selected based on revenue share and the strength of their portfolio across at least two of these market segments. Revenue share is categorized as high (10% or more), medium (2%-9%), or low (less than 2% or absence of a strong product portfolio). The analysis highlights 13 companies that generated revenue from these solutions between 2021 and 2024.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Table of Contents

Strategic Imperative and Growth Environment

Frost RadarTM: Laboratory Automation Systems

Frost RadarTM: Companies to Action

  • Abbott
  • Agilent Technologies
  • Azenta Life Sciences
  • BD
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Eppendorf
  • Hamilton Company
  • Revvity
  • Roche Diagnostics
  • Siemens Healthineers
  • Tecan
  • Thermo Fisher Scientific

Best Practices & Growth Opportunities

Frost Radar Analytics

Next Steps: Leveraging the Frost Radar to Empower Key Stakeholders

  • Significance of Being on the Frost Radar
  • CEO's Growth Team
  • Investors
  • Customers
  • Board of Directors

Next Steps

Legal Disclaimer